Showing results (1141-1150 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|July 8, 2000
Time-schedule dependency of S 16020, a new topoisomerase II inhibitorJ Soudon, G Milano, M G Poullain, et al.
Anti-Cancer Drugs|July 18, 2000
Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to childrenS Eksborg, S Söderhäll, M Frostvik-Stolt, et al.
Anti-Cancer Drugs|July 18, 2000
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The NetherlandsKruijtzer CMF, J Verweij, J H Schellens, et al.
Anti-Cancer Drugs|July 18, 2000
Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assayM Breidenbach, D Rein, T Schmidt, et al.
Anti-Cancer Drugs|July 18, 2000
Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicinT Cufer, M Pfeifer, I Vrhovec, et al.
Anti-Cancer Drugs|November 15, 2001
Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell linesM Wu, B Wang, E M Perchellet, et al.
Anti-Cancer Drugs|November 15, 2001
Phase I-II study of neoadjuvant chemoradiotherapy followed by radical surgery in locally advanced cervical cancerH Tsuda, M Tanaka, T Manabe, et al.
Anti-Cancer Drugs|November 15, 2001
Quantification of doxorubicin in plasma--a comparative study of capillary and venous blood samplingC Palm, O Björk, M Björkholm, et al.
Anti-Cancer Drugs|June 5, 2002
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancerAkihisa Fujita, Toshihiko Ohkubo, Hideaki Hoshino, et al.
Anti-Cancer Drugs|July 19, 2001
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorinA A Garcia, F M Muggia, C P Spears, et al.
Pageof 464